Show simple item record

dc.contributor.authorSalati, M
dc.contributor.authorBraconi, C
dc.date.accessioned2019-04-17T09:59:56Z
dc.date.issued2019-02-01
dc.identifier.citationSeminars in liver disease, 2019, 39 (1), pp. 13 - 25
dc.identifier.issn0272-8087
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3190
dc.identifier.eissn1098-8971
dc.identifier.doi10.1055/s-0038-1676097
dc.description.abstractCholangiocarcinomas (CCAs) are tumors with a dismal prognosis. Early diagnosis is a key challenge because of the lack of specific symptoms, and the curability rate is low due to the difficulty in achieving a radical resection and the intrinsic chemoresistance of CCA cells. Noncoding RNAs (ncRNAs) are transcripts that are not translated into proteins but exert their functional role by regulating the transcription and translation of other genes. The discovery of the first ncRNA dates back to 1993 when the microRNA (miRNA) lin-4 was discovered in Caenorhabditis elegans. Only 10 years later, miRNAs were shown to play an oncogenic role in cancer cells and within 20 years miRNA therapeutics were tested in humans. Here, the authors review the latest evidence for a role for ncRNAs in CCA and discuss the promise and challenges associated with the introduction of ncRNAs into clinical practice.
dc.formatPrint-Electronic
dc.format.extent13 - 25
dc.languageeng
dc.language.isoeng
dc.publisherTHIEME MEDICAL PUBL INC
dc.rights.urihttps://www.rioxx.net/licenses/under-embargo-all-rights-reserved
dc.subjectHumans
dc.subjectCholangiocarcinoma
dc.subjectBile Duct Neoplasms
dc.subjectLiver Neoplasms
dc.subjectMicroRNAs
dc.subjectGene Expression Regulation, Neoplastic
dc.subjectTumor Microenvironment
dc.subjectRNA, Long Noncoding
dc.subjectCarcinogenesis
dc.titleNoncoding RNA in Cholangiocarcinoma.
dc.typeJournal Article
rioxxterms.versionofrecord10.1055/s-0038-1676097
rioxxterms.licenseref.urihttps://www.rioxx.net/licenses/under-embargo-all-rights-reserved
rioxxterms.licenseref.startdate2019-02
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfSeminars in liver disease
pubs.issue1
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Signal Transduction & Molecular Pharmacology
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Signal Transduction & Molecular Pharmacology
pubs.publication-statusPublished
pubs.volume39
pubs.embargo.termsNot known
icr.researchteamSignal Transduction & Molecular Pharmacology
dc.contributor.icrauthorBraconi, Chiara


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record